Millions of travelers in the United States can now look forward to a more comfortable journey following the recent approval of a groundbreaking medication by the US Food and Drug Administration (FDA). The FDA has authorized the use of *Tradipitant*, an oral neurokinin-1 (NK-1) receptor antagonist developed by *Vanda Pharmaceuticals*, marking the first new treatment for motion sickness in over four decades. This medication, to be marketed under the brand name *Nereus*, is set to provide significant relief for individuals affected by motion-induced vomiting.
The development of *Nereus* represents a significant advancement in the treatment landscape for motion sickness, which affects approximately 30% of adults. Traditional remedies, primarily antihistamines, have been the standard for nearly 40 years, but they often come with side effects such as drowsiness and limited effectiveness. In contrast, *Nereus* offers a modern solution, as noted by Vanda’s CEO, *Mihael Polymeropoulos*, who stated, “For the first time in over 40 years, patients have access to a novel therapy grounded in modern neuropharmacology, offering effective prevention without the limitations of existing options.”
How Nereus Works
*Nereus* operates by blocking the NK-1 receptor in the brainstem, which plays a crucial role in the vomiting reflex that is triggered by the neurotransmitter substance P. By inhibiting this pathway, the drug effectively reduces instances of motion-induced vomiting. The FDA’s decision was informed by three clinical trials, including two Phase III real-world studies conducted with participants traveling on boats. Results indicated that *Nereus* significantly outperformed a placebo in reducing vomiting episodes.
Despite concerns regarding the long-term safety of the drug, both Vanda Pharmaceuticals and the FDA concluded that motion sickness is typically an acute condition. Therefore, it is recommended that individuals do not use this medication for extended periods. This approach aligns with the FDA’s commitment to ensuring patient safety while expanding treatment options.
Future Prospects for Nereus
*Nereus* is expected to be available in pharmacies within a few months, with ongoing studies planned to explore its potential in treating other conditions such as gastroparesis and nausea associated with weight-loss medications. The outcomes of these trials may further expand the therapeutic applications of *Tradipitant*, solidifying its role in modern medicine.
The trial results have been published in the journal *Frontiers in Neurology*, showcasing the importance of continued research and development in the field of motion sickness treatment. As the first new medication in over 40 years, *Nereus* represents a promising leap forward for those who experience the discomfort of motion sickness, paving the way for more effective interventions in the future.
